Previous close | 8.50 |
Open | 8.57 |
Bid | 8.69 x 100 |
Ask | 8.73 x 600 |
Day's range | 8.46 - 8.88 |
52-week range | 2.74 - 12.00 |
Volume | |
Avg. volume | 2,011,930 |
Market cap | 1.922B |
Beta (5Y monthly) | 1.61 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.46 |
Earnings date | 06 May 2024 - 10 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 11.17 |
Director Patrick Yang has sold 25,000 shares of Sana Biotechnology Inc (NASDAQ:SANA), according to a recent SEC Filing.
Baillie Gifford (Trades, Portfolio), the renowned investment management firm, has recently expanded its investment portfolio by adding a significant number of shares in Sana Biotechnology Inc (NASDAQ:SANA). This move underscores the firm's confidence in the biotechnology company's growth potential. On February 1, 2024, Baillie Gifford (Trades, Portfolio) acquired an additional 210,603 shares of Sana Biotechnology, reflecting a 2.07% change in their holdings and bringing the total shares owned to 10,360,620.
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory NHL and CLL suggest ability to dose safely, demonstrate the desired immune evasion profile, and early clinical efficacy using hypoimmune technology Announced SC291 IND clearance for B-cell mediated autoimmune diseases with goal to report initial clinical data in 2024 Announced SC262 IND